Latest Headlines

Latest Headlines

Bayer to pay $160M as part of Onyx settlement

Bayer and Onyx Pharmaceuticals have resolved a longstanding dispute over the rights to a Nexavar follow-up drug. Bayer will pay $160 million plus royalties and give co-marketing rights to Onyx in

Bayer inks pledge to J.V. with Russia's Yunona

Bayer is the latest drugmaker to team up with a Russian company. The German-based conglomerate's healthcare division has inked a preliminary agreement with Yunona Holdings, which has government

Bayer settles Onyx spat with $160M payout, sales rights and royalties

Longtime partners Onyx Pharmaceuticals and Bayer have patched up a long-running dispute over who owns the rights to a Phase III cancer drug that bears a close resemblance to the blockbuster Nexavar

Dekkers uses tennis lessons at Bayer's helm

We're beginning to think pharma boards have one screening question for CEO candidates: Did you ever engage in competitive sports? Recent executive profiles have told us Novartis ($NVS) CEO Joe

Bayer's Xarelto could gain edge from new ACS trial

Bayer CEO Marijn Dekkers has been resolute in his multibillion-dollar predictions for the company's new bloodthinner Xarelto, developed in partnership with Johnson & Johnson ($JNJ), despite every

J&J and Bayer's Xarelto wins where Pfizer drug lost

The blood-thinner Xarelto has added some upbeat Phase III data to its resume. Bayer ($BAYN), which is co-developing the drug with Johnson & Johnson ($JNJ), said the drug met its primary efficacy

FDA turns to advisory panel for Yaz safety analysis

FDA has called in the cavalry for help reviewing the safety of Bayer's Yaz line of birth-control pills. The agency plans to convene an advisory panel in December to sift through the evidence on the

Bayer, union at odds over outsourcing promised jobs

The union representing some 500 Bayer employees in California is playing hardball with the German drugmaker. Union officials are suggesting the workers may cancel the three-year-old agreement between

Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field

The experimental prostate cancer drug Alpharadin took center stage at the big EMCC meeting in Stockholm, with researchers reporting that they had suspended a registration trial after

Xarelto tees up big new European approval

Bayer's ($BAY) new anticoagulant drug Xarelto won a crucial recommendation for European approval for the prevention of stroke in patients with atrial fibrillation. The drug was already approved to